Text Size

An Evaluation of the Effect of the AmnioFix Amniotic Membrane Allograft in Patients Undergoing Posterior Instrumentation Removal

This study is currently recruiting participants.
Verified September 2012 by MiMedx Group, Inc.
Sponsor:
Information provided by (Responsible Party):
MiMedx Group, Inc.
ClinicalTrials.gov Identifier:
NCT01357187
First received: May 18, 2011
Last updated: September 17, 2012
Last verified: September 2012
History of Changes
  Purpose

The objective of this study is to evaluate the clinical effectiveness of AmnioFix™ in the reduction of the tenacity and frequency of soft tissue adhesions during the removal of segmental posterior lumbar instrumentation.


Condition Intervention
Adhesions of Soft Tissue
 Other: Scheduled removal of posterior instrumentation with AmnioFix
Other: Scheduled removal of posterior instrumentation without AmnioFix

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: An Evaluation of the Effect of the AmnioFix™ Amniotic Membrane Allograft on Scar Tissue and Adhesions in Patients Undergoing Posterior Instrumentation Removal

Resource links provided by NLM:

MedlinePlus related topics: Adhesions Scars
U.S. FDA Resources

Further study details as provided by MiMedx Group, Inc.:

Primary Outcome Measures:
  • Tenacity and frequency of soft tissue adhesion [ Time Frame: At the time of removal of segmental posterior lumbar instrumentation ]

Secondary Outcome Measures:
  • Presence and extent of scar tissue using histological analysis of the lumbar tissue adjacent to the surgical site [ Time Frame: At the time of removal of segmental posterior lumbar instrumentation ]
  • Number of intra-operative complications [ Time Frame: At the time of removal of segmental posterior lumbar instrumentation ]

Estimated Enrollment: 50
Study Start Date: September 2011
Arms Assigned Interventions
Control Other: Scheduled removal of posterior instrumentation without AmnioFix
Experimental: Treatment Other: Scheduled removal of posterior instrumentation with AmnioFix

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Adults (18 years or older)
  • Diagnosed with lumbar pathology requiring elective lumbar interbody fusion
  • Willingness to comply to follow-up examinations and diagnostic imaging procedures
  • Ability to give full written informed consent

Exclusion Criteria:

  • Previous surgical procedure performed at same site
  • Sign or symptoms of other disease which could result in allograft failure
  • Require a corpectomy
  • Participating in another drug or device clinical trial
  • Pregnant or may become pregnant during the study
  • Prisoner
  • Involved in workmen's compensation or other litigation relative to a spine injury
  • Past medical history of allograft implantation which resulted in graft failure
  • Any condition requiring treatment above the normal standard of care
  • Currently taking medications which could affect graft incorporation (supervising physicians discretion)
  • Auto-Immune disease
  • Renal failure
  • Failure to sign or understand informed consent information
  • History of drug and/or alcohol abuse
  • Allergic to aminoglycosides
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01357187

Contacts
Contact: Brian Subach, MD 703-766-5404

Locations
United States, Virginia
Virginia Spine Institute Recruiting
Reston, Virginia, United States, 20190
Contact: Copay     703-766-5404        
Sponsors and Collaborators
MiMedx Group, Inc.
Investigators
Principal Investigator: Brian Subach, MD Virginia Spine Institute
  More Information

No publications provided

Responsible Party: MiMedx Group, Inc.
ClinicalTrials.gov Identifier: NCT01357187     History of Changes
Other Study ID Numbers: #11-06-02
Study First Received: May 18, 2011
Last Updated: September 17, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by MiMedx Group, Inc.:
Lumbar pathology
requiring elective lumbar interbody fusion

Additional relevant MeSH terms:
Tissue Adhesions
Cicatrix
Fibrosis
Pathologic Processes

ClinicalTrials.gov processed this record on May 16, 2013